Cargando…

Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions

Detalles Bibliográficos
Autor principal:	Di Biase, Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Contemporary Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802477/ https://www.ncbi.nlm.nih.gov/pubmed/26892528 http://dx.doi.org/10.1161/JAHA.115.002776

Ejemplares similares

Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke?
por: Cao, Lin, et al.
Publicado: (2015)

An Updated Review of Target‐Specific Oral Anticoagulants Used in Stroke Prevention in Atrial Fibrillation, Venous Thromboembolic Disease, and Acute Coronary Syndromes
por: Cove, Christina L., et al.
Publicado: (2013)

Role of Monocytes in Heart Failure and Atrial Fibrillation
por: Shahid, Farhan, et al.
Publicado: (2018)

Pregnancy Complicated by Valvular Heart Disease: An Update
por: Nanna, Michael, et al.
Publicado: (2014)

Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges
por: Chen, Ashley, et al.
Publicado: (2020)

Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion
por: Warden, Bruce A., et al.
Publicado: (2018)

Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation
por: da Silva, Rose M.F.L.
Publicado: (2014)

Newer Anticoagulants for Non-Valvular Atrial Fibrillation
por: Harburger, Joseph M., et al.
Publicado: (2012)

Direct oral anticoagulants and the risk of osteoporotic fractures in patients with non-valvular atrial fibrillation
por: Kuo, Liang-Tseng, et al.
Publicado: (2021)

Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
por: Dhamane, Amol D., et al.
Publicado: (2022)

2017 Focused Update for Management of Patients With Valvular Heart Disease: Summary of New Recommendations
por: Matiasz, Richard, et al.
Publicado: (2018)

Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure
por: Amin, Alpesh, et al.
Publicado: (2019)

Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients
por: Umei, Masahiko, et al.
Publicado: (2017)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease
por: Moon, Inki, et al.
Publicado: (2019)

Left Atrial Appendage Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Collado, Fareed Moses S., et al.
Publicado: (2021)

Prescribers’ perceptions of benefits and limitations of direct acting oral anticoagulants in non-valvular atrial fibrillation
por: Generalova, Daria, et al.
Publicado: (2020)

Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation
por: Botto, Gianluca, et al.
Publicado: (2021)

Balancing the benefits and harms of oral anticoagulation in non-valvular atrial fibrillation
por: Lindley, Richard I
Publicado: (2021)

Evidence Gaps in the Era of Non–Vitamin K Oral Anticoagulants
por: Aronis, Konstantinos N., et al.
Publicado: (2018)

Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation?
por: Samoš, Matej, et al.
Publicado: (2022)

Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA
por: Dhamane, Amol D, et al.
Publicado: (2021)

Comparison of the New Oral Anticoagulants and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Systematic Review and Meta-Analysis
por: de Souza Lima Bitar, Yasmin, et al.
Publicado: (2019)

Characterization, Pathogenesis, and Clinical Implications of Inflammation‐Related Atrial Myopathy as an Important Cause of Atrial Fibrillation
por: Packer, Milton
Publicado: (2020)

Exploring Refractoriness as an Adjunctive Electrical Biomarker for Staging of Atrial Fibrillation
por: van Staveren, Lianne N., et al.
Publicado: (2020)

Atrial Fibrillation Ablation without Interruption of Anticoagulation
por: Santangeli, Pasquale, et al.
Publicado: (2011)

Direct Acting Oral Anticoagulant vs. Warfarin in the Prevention of Thromboembolism in Patients With Non-valvular Atrial Fibrillation With Valvular Heart Disease—A Systematic Review and Meta-Analysis
por: Martha, Januar Wibawa, et al.
Publicado: (2021)

Guidance on Short‐Term Management of Atrial Fibrillation in Coronavirus Disease 2019
por: Rattanawong, Pattara, et al.
Publicado: (2020)

Clinical factors associated with safety and efficacy in patients receiving direct oral anticoagulants for non-valvular atrial fibrillation
por: Yamato, Hiroshi, et al.
Publicado: (2020)

Thrombotic events and rebleeding after hemorrhage in patients taking direct oral anticoagulants for non-valvular atrial fibrillation
por: Yanagisawa, Daisuke, et al.
Publicado: (2021)

Major Bleeding Risk in Patients With Non-valvular Atrial Fibrillation Concurrently Taking Direct Oral Anticoagulants and Antidepressants
por: Chang, Kuo-Hsuan, et al.
Publicado: (2022)

Psychological effects of treatment with novel oral anticoagulants in non-valvular atrial fibrillation patients
por: Öncel, Can Ramazan
Publicado: (2016)

Trials of Novel Oral Anticoagulants for Stroke Prevention In Patients with Non-valvular Atrial Fibrillation
por: Halperin, Jonathan L, et al.
Publicado: (2014)

Oral anticoagulants and concurrent rifampin administration in tuberculosis patients with non-valvular atrial fibrillation
por: Hwang, Ki Won, et al.
Publicado: (2023)

Suboptimal oral anticoagulant treatment among Chinese non-valvular atrial fibrillation patients: the Nanchang Atrial Fibrillation Project
por: Xiong, Qinmei, et al.
Publicado: (2016)

Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation
por: Birkinshaw, Alexander, et al.
Publicado: (2020)

Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease
por: Briasoulis, Alexandros, et al.
Publicado: (2018)

Association between direct-acting oral anticoagulants vs. warfarin with the risk of osteoporosis in patients with non-valvular atrial fibrillation
por: Akhtar, Tauseef, et al.
Publicado: (2020)

Infarct Volumes of Patients with Acute Ischemic Stroke Receiving Direct Oral Anticoagulants due to Non-Valvular Atrial Fibrillation
por: Yavasoglu, Nese G., et al.
Publicado: (2021)

Oral Anticoagulant Use in Elderly Japanese Patients With Non-Valvular Atrial Fibrillation　― Subanalysis of the ANAFIE Registry ―
por: Akao, Masaharu, et al.
Publicado: (2020)

Oral Anticoagulation in Patients with Chronic Kidney Disease and Non-Valvular Atrial Fibrillation: The FAERC Study
por: Montomoli, Marco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mvbskllkpdn4rm0sv1mpvr0879